Evidence map›Paper›PMID 41346599›Full record

ArticleFrontiers in immunology2025

Neutrophil dysregulation differentiates pediatric septic shock biomarker-based mortality-risk strata: insights from weighted gene co-expression network and transcriptomic analyses.

Leland Dunwoodie, Min Huang, Andrew R Moore, Natalja L Stanski, Stephen W Standage, Jennifer M Kaplan, Basilia Zingarelli, Kelli Harmon, Julie C Fitzgerald, Scott L Weiss and 10 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Leland DunwoodieDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Min HuangDepartment of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, United States.
Andrew R MooreStanford Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, United States.
Natalja L StanskiDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Stephen W StandageDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Jennifer M KaplanDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Basilia ZingarelliDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Kelli HarmonDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Julie C FitzgeraldChildren's Hospital of Philadelphia, Philadelphia, PA, United States.
Scott L WeissNemours Children's Hospital, Wilmington, DE, United States.
Michael T BighamAkron Children's Hospital, Akron, OH, United States.
Adam J SchwarzChildren's Hospital of Orange County, Orange, CA, United States.
Riad LutfiRiley Hospital for Children, Indianapolis, IN, United States.
Neal J ThomasPenn State Hershey Children's Hospital, PA, United States.
Bereketeab HaileselassieLucile Packard Children's Hospital Stanford, Palo Alto, CA, United States.
Parag N JainHeart Center, Children's Health, Division of Cardiology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Timothy E SweeneyInflammatix, Sunnyvale, CA, United States.
Rishikesan KamaleswaranDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Mihir R AtreyaDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Andrew J LautzDivision of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Funding

Leveraging multi-omics to maximize the scientific value of pediatric sepsis biorepository and advance patient endotypingR33GM151703 · NIGMS · CINCINNATI CHILDRENS HOSP MED CTR · PI Mihir R Atreya, Rishikesan Kamaleswaran · 2025 to 2026
$1.4M
Translational approaches to unravel organ-specific microvascular endothelial responses in sepsis.R35GM155165 · NIGMS · CINCINNATI CHILDRENS HOSP MED CTR · PI Mihir R Atreya · 2024 to 2026
$1.2M
Developing a Precision Medicine Approach to Pediatric Sepsis-Associated Acute Kidney Injury: Identification of Unique Subphenotypes and Strategies for Bedside ImplementationK23GM151444 · NIGMS · CINCINNATI CHILDRENS HOSP MED CTR · PI Natalja L. Stanski · 2023 to 2026
$769k
Mechanisms of cardiomyocyte dysfunction in pediatric septic shockK08GM148957 · NIGMS · CINCINNATI CHILDRENS HOSP MED CTR · PI Andrew John Lautz · 2023 to 2026
$768k
Leveraging multi-omics to maximize the scientific value of pediatric sepsis biorepository and advance patient endotypingR21GM151703 · NIGMS · CINCINNATI CHILDRENS HOSP MED CTR · PI ATREYA, MIHIR R, KAMALESWARAN, RISHIKESAN · 2023 to 2024
$459k
Establishment of a multi-center biobank of patient-specific induced pluripotent stem cells for pediatric sepsis researchR21GM150093 · NIGMS · CINCINNATI CHILDRENS HOSP MED CTR · PI ATREYA, MIHIR R, LAUTZ, ANDREW JOHN · 2023 to 2024
$431k
NIGMS NIH HHS K08 GM148957NIGMS NIH HHS K23 GM151444NIGMS NIH HHS L40 GM134527NIGMS NIH HHS R21 GM150093NIGMS NIH HHS R21 GM151703NIGMS NIH HHS R33 GM151703NIGMS NIH HHS R35 GM155165
6 · The paper itself

Abstract

Background: Pediatric sepsis is a leading cause of global mortality, particularly among children, with limited therapeutic options beyond antibiotics and organ support. The Pediatric Sepsis Biomarker Risk Model (PERSEVERE-II) stratifies mortality risk in pediatric septic shock, yet the molecular mechanisms underlying high mortality risk remain incompletely understood. Methods: We analyzed whole blood transcriptomes collected from 81 children with septic shock on day 1 of meeting study criteria. Patients were stratified into high- and low-mortality risk groups according to the PERSEVERE-II biomarker risk model. Using weighted gene co-expression network analysis (WGCNA) and differential gene expression analyses, we identified molecular pathways and transcription factors (TFs) associated with mortality risk. Cell type differences were inferred using CIBERSORTx and using a reference single-cell dataset inclusive of neutrophils and their subsets. Findings: We identified distinct molecular profiles with high-risk patients displaying significant overexpression of genes related to neutrophil degranulation and innate immunity, alongside suppressed adaptive immune responses. The predominance of developing neutrophils underscored a major role of emergency granulopoiesis. Key TFs identified, including Interpretation: Our results suggest that neutrophil dysregulation underpins the high mortality risk conferred by the PERSEVERE-II model. The identified transcriptional regulators may provide potential targets to mitigate neutrophil dysregulation and improve outcomes among high-risk patients.

Indexed as

Gene Regulatory NetworksNeutrophilsShock, SepticTranscriptomeAdolescentBiomarkersChildChild, PreschoolFemaleGene Expression ProfilingHumansInfantMaleBiomarkersimmune responsemortality risk stratificationneutrophil dysregulationpediatric sepsisprecision medicinetranscriptomics

Identifiers

PMID41346599
PMCPMC12672347

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.